Hong-Kong based Value Measured Investment Limited led a $10 million Series B financing in Sirnaomics, Inc., a biopharmaceutical company focusing on RNAi therapeutics. The funding will go towards development of anti-fibrosis treatments, with a Phase I clinical trial planned for early second half of 2016.